Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedAdded a site-wide revision note (Revision: v3.3.3) and removed the HHS Vulnerability Disclosure link along with Revision: v3.3.2; these are UI/policy updates and do not alter the clinical trial record data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check32 days agoChange DetectedRevision: v3.3.1 was added and revision: v3.2.0 was removed.SummaryDifference0.1%

- Check39 days agoChange DetectedThe government funding/status notice banner was removed from the page, and it does not affect the trial record or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check53 days agoChange DetectedDifference0.1%

- Check82 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference9%

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.